Jardiance

Selected form

Empagliflozin

Method of action: Antidiabetic, Drugs Used In Diabets

Treatment option: Cerebrovascular Accident, Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jardiance

Property	Description
Active ingredient	Empagliflozin
Form	Tablet (Oral administration)
Pharmacological class	Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor
General Purpose	Lowers elevated glucose and supports cardiovascular/renal function
Origin	Synthetic compound (Glucopyranoside derivative)

What Type of Medicine is Jardiance?

Jardiance is a specialized, prescription medicine containing the active ingredient Empagliflozin, which is classified as a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor. This drug class works via an insulin-independent mechanism, meaning its primary action is distinct from agents that influence insulin production or sensitivity. Empagliflozin is a synthetic compound designed for highly selective targeting of the SGLT2 protein, a feature clinically recognized as differentiating it from older glucose-lowering therapies.

Composition and Pharmaceutical Form

The medicine is supplied as a tablet intended for oral administration, and it is formulated as a single-ingredient product containing only Empagliflozin and inert excipients. This single-agent composition simplifies its integration into existing therapeutic regimens. This form is distinct from combination therapies, such as the product Synjardy, which includes Empagliflozin alongside other active substances.

General Therapeutic Purpose of Empagliflozin

The general purpose of Empagliflozin is to promote metabolic balance by reducing elevated glucose concentrations in the blood. It achieves this by causing renal glucose reabsorption inhibition, effectively blocking the SGLT2 protein, which results in Glucosuria, the necessary excretion of sugar in the urine. Beyond this glucose-lowering function, the drug's mechanism also provides ancillary effects, including natriuresis and osmotic diuresis by influencing sodium and fluid handling. Clinical evidence has established that the drug provides significant support to the cardiovascular and renal systems, making the medicine clinically recognized for its ability to provide a broader range of support to adults with established cardiovascular conditions.

Regulatory References

cardiovascular

What side effects are possible with Jardiance?

Possible Side Effects and Safety Information

The safety profile of Empagliflozin is established through official regulatory documents, which classify adverse reactions based on frequency and body system involvement.

Official Adverse Reactions by Frequency and System-Organ Class

The most commonly documented side effects (ge 1/100) include genital mycotic infections (e.g., vaginal candidiasis, balanitis) and urinary tract infections. Effects related to increased fluid excretion, such as increased urination, thirst, and volume depletion (which may manifest as dizziness), are also common and are noted to occur more frequently at the start of treatment. Hypoglycemia (low blood sugar) is classified as a Very Common occurrence when Empagliflozin is used alongside insulin or sulfonylureas.

Classification	Examples of Reactions	Affected System-Organ Class
Common	Genital infections, Volume depletion, Dyslipidaemia	Infections, Metabolism, Renal and Urinary
Rare	Diabetic Ketoacidosis (DKA), Fournier's Gangrene	Metabolism, Infections

Serious Adverse Reactions

The regulatory labeling documents rare but serious adverse reactions, including Diabetic Ketoacidosis (DKA), which may occur even with normal blood sugar levels. A rare but serious infection known as Necrotizing Fasciitis of the Perineum (Fournier's Gangrene) is also officially listed. Serious urinary tract infections, such as urosepsis and pyelonephritis, and severe hypersensitivity reactions (e.g., angioedema) have also been documented.

Safety Considerations for Specific Populations and Use

Official safety notes caution that older adults (ge 65 years) may be at an increased risk of volume depletion-related adverse reactions. The medicine is not recommended for individuals with Type 1 Diabetes Mellitus due to the increased risk of DKA. It is also generally restricted from use in patients with severe renal impairment due to a lack of glucose-lowering efficacy in that population, and is contraindicated in individuals with a known history of serious hypersensitivity to Empagliflozin.

Overdose and Emergency Response

The official regulatory documents indicate that the management of a suspected Jardiance (Empagliflozin) overdose is focused primarily on monitoring and providing general supportive measures. Clinical studies involving single doses up to 800 mg did not identify specific acute signs of toxicity. Crucially, regulatory authorities confirm that no specific antidote has been identified to counteract the effects of Empagliflozin.

The regulatory labeling mandates that immediate medical attention must be sought and the product discontinued if a severe, life-threatening complication such as Diabetic Ketoacidosis (DKA) is suspected. DKA is a serious metabolic crisis that requires prompt evaluation and hospitalization.

Symptoms that trigger this mandated urgent action, as described in official documents, include nausea, vomiting, stomach-area (abdominal) pain, trouble breathing, or unusual tiredness. These clinical manifestations signal the need for emergency support regardless of the patient's blood glucose levels.

Regulators also note population-specific considerations: patients who are elderly or have renal impairment carry an increased risk of adverse reactions related to volume depletion, which may contribute to the severity of an overdose scenario. Management must focus on the symptomatic presentation of these serious outcomes.

Therapeutic Uses of Jardiance

Jardiance (Empagliflozin) is commonly used to provide therapeutic support across major chronic disease domains, addressing symptomatic areas related to metabolic imbalance and organ-specific functional stress. The medication's therapeutic uses are considered relevant in these complex conditions.

The medication may assist with supporting more stable blood sugar levels in adults and pediatric patients with Type 2 Diabetes. Beyond metabolic care, this therapy is considered relevant in cardiovascular and renal health, offering supportive management for chronic Heart Failure (across the HFrEF and HFpEF spectrums) and for Chronic Kidney Disease to manage its progression.

Key Therapeutic Benefits

This medication provides vital support, which contributes to easing the overall symptom burden in patients with established disease. It is considered relevant for easing the risk of major acute events like hospitalization and may help ease the rate at which chronic kidney disease progresses, assisting patients with maintaining stability during difficult long-term symptomatic periods.

“The therapy is commonly used during phases when symptoms become more noticeable and when supportive relief is needed for chronic conditions involving functional stress.”

Quick Fact

Quick Fact: Supportive Management for Systemic Imbalance

This drug is applied across domains where additional symptomatic support is needed. It may assist with managing high blood sugar symptoms and assists with managing the burden associated with chronic cardiovascular and renal functional decline.

Eligibility and Restrictions for Use

Who Can and Cannot Use Jardiance (Empagliflozin)?

The eligibility for Jardiance is strictly defined by regulatory criteria relating to age, medical conditions, and physiological status.

Contraindications and Prohibited Use

Jardiance is contraindicated in patients with a history of serious hypersensitivity reaction to empagliflozin or any of its components. It is also prohibited in individuals with End-Stage Renal Disease (ESRD) or those on dialysis.

The medicine is not recommended for use in patients with Type 1 Diabetes Mellitus (T1DM) due to the associated increased risk of diabetic ketoacidosis.

Population and Condition-Based Restrictions

Category	Official Regulatory Rule
Renal Function	Use for improving blood sugar levels is not recommended in patients with an estimated GFR ( eGFR) less than 30 mL/min/1.73 m^2.
Age Group	Approved for children aged 10 years and older for Type 2 Diabetes Mellitus only. Safety/effectiveness for Heart Failure or CKD is not established for those under 18.
Hepatic Function	Not recommended for use in patients with severe hepatic impairment (limited experience).
Pregnancy/Lactation	Not recommended during the second and third trimesters of pregnancy or while breastfeeding.
Specific CKD	Not recommended for treating chronic kidney disease in patients with polycystic kidney disease.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Jardiance (Empagliflozin) has specific documented interactions, primarily based on additive or synergistic effects on the body (pharmacodynamics), rather than changes to drug metabolism (pharmacokinetics).

Pharmacodynamic Interactions

Interacting Product Category	Potential Effect	Constraint / Implication
Insulin & Insulin Secretagogues (e.g., Sulfonylureas)	Increased risk of hypoglycemia (low blood sugar) due to additive glucose-lowering effects.	Dosage reduction of the co-administered insulin or secretagogue may be necessary.
Diuretics (e.g., Loop Diuretics)	Increased risk of volume depletion (dehydration) and hypotension (low blood pressure).	Volume status and renal function should be assessed before starting and monitored closely during co-administration.

Pharmacokinetic & Other Interactions

Empagliflozin is cleared primarily by UGT glucuronidation and is determined to not inhibit or induce CYP450 enzymes or major drug transporters (P-gp, OATPs). Consequently, no clinically relevant changes in drug exposure have been noted for numerous commonly co-administered medicines, including Warfarin, Digoxin, and Simvastatin.

However, co-administration with Lithium may result in a decrease in serum lithium concentrations, requiring careful monitoring of lithium levels.

Procedural & Substance Constraints

Major Surgery/Prolonged Fasting: Treatment must be withheld for at least 3 days (72 hours) prior to major surgery or procedures associated with prolonged fasting to reduce the risk of ketoacidosis.
Alcohol/Fasting: Excessive alcohol intake and prolonged fasting are officially documented as risk factors that may predispose patients to ketoacidosis, emphasizing that these conditions require monitoring or temporary discontinuation.

Mechanism of Action

The mechanism of action of Empagliflozin is fundamentally insulin-independent, acting directly within the renal and cardiovascular systems to modulate key physiological pathways.

Selective SGLT2 Inhibition and Glucosuria

Empagliflozin acts as a highly selective inhibitor of the Sodium-Glucose Co-Transporter 2 ( SGLT2) protein, which is primarily located in the proximal tubules of the kidneys. SGLT2 is responsible for the majority of filtered glucose reabsorption. By blocking this transport protein, the drug prevents this reabsorption process, thereby forcing the excretion of glucose into the urine, a process termed glucosuria. This action results in a reduction of plasma glucose concentrations, independent of the body's insulin status.

Volume Modulation and Renal Hemodynamic Adjustment

The inhibition of SGLT2 also prevents the coupled reabsorption of sodium ions. This leads to increased sodium and water delivery to the distal tubule, causing natriuresis (sodium excretion) and osmotic diuresis (water excretion). The resultant modest reduction in circulating fluid volume mediates a decrease in cardiac preload and afterload. Concurrently, this increased sodium delivery activates the Tubuloglomerular Feedback mechanism, which narrows the kidney's afferent arteriole, thereby mediating a reduction in intraglomerular pressure.

Cardiometabolic Fuel Shift

A systemic consequence of the drug's mechanism is a metabolic shift that favors the utilization of ketone bodies (beta-hydroxybutyrate) as an energy substrate. The increased excretion of glucose and calories is hypothesized to promote this shift, which is associated with enhanced efficiency of energy production within the heart muscle. This metabolic action contributes to the drug's overall systemic physiological profile.

Dosage and Administration Information

How to use Jardiance

Jardiance is a film-coated tablet containing the active substance empagliflozin, intended for oral administration. Established guidelines for its use focus on consistent daily scheduling and standardized dosing.

Administration Scope

Instruction	Details
Route of administration	Oral administration, as a film-coated tablet.
Dosing schedule	The starting and recommended dose is 10 mg once daily for all approved uses. For adults with Type 2 Diabetes, the dose may be increased to a maximum of 25 mg once daily if additional blood glucose lowering is required.
Frequency and timing	Administered once daily (qDay), generally taken in the morning.
Timing in relation to meals	May be taken with or without food and should be swallowed whole with water.
Age-group administration rules	Pediatric patients (10 years and older) with Type 2 Diabetes follow the same regimen: start at 10 mg once daily, titrating up to a 25 mg maximum.
Missed-dose rules	If a dose is missed, take it as soon as remembered. The subsequent dose must not be doubled to compensate.
Special procedural conditions	The medicine is directed to be withheld for at least 3 days prior to major surgery or procedures involving prolonged fasting.

Resulting Procedural Structure

Step sequence:

Take the prescribed strength (10 mg or 25 mg) of the film-coated tablet once daily.
Consume the tablet in the morning, swallowing it whole with water, regardless of meals.
If a dose is missed, take it as soon as remembered, but never take two doses in one day.

Connection to the overall use protocol (2–4 sentences): The instructions establish a standardized, once-daily, oral use protocol that is independent of meal consumption. These guidelines specify the two dose levels, 10 mg and 25 mg, and detail the procedural steps for handling missed doses and the required pre-surgical withholding period, ensuring consistent administration across all labeled indications.

Recent Clinical Evidence

Jardiance: Recent Clinical Evidence

Evidence for Metabolic and Glycemic Control

The use of empagliflozin was evaluated in Randomized Controlled Trials (RCTs) covering adults and pediatric patients (aged 10+) with Type 2 Diabetes Mellitus. Research monitored blood sugar markers, including Glycated Hemoglobin ( HbA1c). Findings described patterns where average HbA1c and Fasting Plasma Glucose measurements showed patterns of being lower in the studied populations compared to placebo. Research notes that the ability to influence blood sugar may diminish in patients with severe renal impairment.

Evidence for Cardiovascular and Heart Failure Health

Dedicated Cardiovascular Outcomes Trials and RCTs explored the medicine's association with heart events. In adults with Type 2 Diabetes and established cardiovascular disease, data show patterns related to a lower rate of the MACE composite endpoint, primarily linked to lower rates of cardiovascular death and hospitalization for heart failure.

Studies in Chronic Heart Failure (Reduced and Preserved Function)

Specific studies also explored Chronic Heart Failure across the full spectrum. For both Heart Failure with Reduced Ejection Fraction ( HFrEF) and Heart Failure with Preserved Ejection Fraction ( HFpEF), data show patterns related to a lower rate of the primary composite outcome (cardiovascular death or hospitalization for heart failure) in the studied groups. The evidence in these areas applies to patients both with and without coexisting diabetes.

Evidence for Chronic Kidney Disease (CKD) Progression

A dedicated Renal Outcomes Trial was conducted on a broad CKD population. The studies reported that data show patterns related to a lower rate of the composite primary endpoint (kidney disease progression or cardiovascular death). Research also highlights changes where the rate of kidney function decline ( eGFR) was slower in the observed populations compared to placebo.

Research Landscape Uncertainty

The generalizability of findings is limited, as the results apply only to the specific populations studied, which were often highly selected (e.g., those with established cardiovascular disease). Comparative evidence against other similar medicines is not well established, as the primary large trials studied the drug against an inactive placebo. Furthermore, data for long-term functional status and certain subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Jardiance (FAQ)

Q: Can I take Jardiance if I have an eGFR below 30 mL/min/1.73 m^2?

According to official regulatory documents, Jardiance is contraindicated (prohibited from use) for improving blood sugar control in patients with an estimated GFR ( eGFR) that is persistently less than 30 mL/min/1.73 m^2. Official labeling states the medication is also contraindicated in individuals with end-stage renal disease or those on dialysis.

Q: What do I do if I forget to take my morning dose?

If a dose is missed, official product information advises taking it as soon as it is remembered. Regulatory instructions state that the subsequent dose must not be doubled to compensate for the missed dose.

Q: What are the common side effects of Jardiance?

Official labeling lists several common adverse reactions, including urinary tract infections and genital mycotic infections. Other frequently reported effects are related to fluid excretion, such as increased urination and thirst. When Jardiance is taken alongside insulin or sulfonylureas, low blood sugar (hypoglycemia) is classified as a very common occurrence.

Q: Is there a maximum age limit for taking Jardiance?

There is no definitive maximum age limit specified in the official prescribing information for Jardiance. However, official labeling notes that individuals aged 65 and older may experience a higher risk of adverse reactions related to reduced body fluid volume and kidney function.

Q: How long before surgery do I need to stop taking Jardiance and when can I restart it?

Official guidance mandates that the medication be withheld for at least 3 days prior to planned major surgery or procedures involving prolonged fasting. Treatment is typically resumed once the individual is clinically stable and has restarted oral intake.

Q: What is the difference between Jardiance and Synjardy?

Jardiance is a single-ingredient product containing only empagliflozin. Synjardy is a combination medication that contains empagliflozin along with a second active ingredient, which is metformin hydrochloride.

Q: What should I do if I accidentally overdose on Jardiance?

In the event of a suspected overdose, patients should seek immediate medical assistance. Official information notes that treatment should be based on the patient's clinical status and that empagliflozin is not expected to be removed by hemodialysis.

Q: Does Jardiance have a weight loss effect?

Clinical trial data has indicated that treatment with empagliflozin was associated with a reduction in both body weight and blood pressure compared to a placebo. The reduction is a documented systemic consequence of the drug's mechanism, which involves the excretion of glucose.

Q: Can Jardiance be crushed or split if I have trouble swallowing tablets?

Official dosing instructions direct patients to take the film-coated tablet by mouth once daily. Because specific crushing or splitting guidance is absent from the official label, individuals experiencing difficulty should seek advice from a healthcare professional or pharmacist.

Q: How soon after starting Jardiance will I see changes in my blood sugar?

Empagliflozin's action of increasing the amount of glucose excreted in the urine begins shortly after the first dose. However, the overall effectiveness on long-term blood sugar control is typically assessed by clinicians using markers such as Glycated Hemoglobin ( A1C) over a period of weeks to months.

How should Jardiance be stored and disposed of?

Official Storage and Disposal Requirements

Jardiance (empagliflozin) tablets must be stored according to specific regulatory conditions to maintain product stability and ensure safety.

Requirement Area	Labeled Mandate
Storage Temperature	Store at controlled room temperature, mathbf20^circC to mathbf25^circC (mathbf68^circF to mathbf77^circF), with permitted excursions up to mathbf30^circC.
Environmental Control	Store away from excess heat and moisture; storage in the bathroom is prohibited.
Packaging	Keep the medicine in its original container, tightly closed. Do not use after the expiration date on the package.
Child Safety	The medication must be kept out of the sight and reach of children (and utilizing safety caps is advised).
Disposal	Dispose of unused or expired product according to local regulations. Do not dispose of medicine via wastewater or household waste to protect the environment.